GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction,Nature Reviews Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Nat. Rev. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction
Nature Reviews Gastroenterology & Hepatology ( IF 45.9 ) Pub Date : 2024-09-06 , DOI: 10.1038/s41575-024-00977-2
Jonathan Goldney _{1,

2} , Melanie J Davies _{1,

2}

Affiliation

Guidelines currently recommend organ-specific management of obesity-related complications. Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying obesity-related complications, with further trials underway. These medications enable cause-specific management of obesity complications.

中文翻译：

GLP1 激动剂：代谢功能障碍患者临床试验的当前和未来前景

目前指南建议对肥胖相关并发症进行器官特异性管理。激动胰高血糖素样肽 1 受体的药物，包括共同激动其他厌食激素受体的药物，可显着减轻体重，并为患有各种肥胖相关并发症的人带来好处，进一步的试验正在进行中。这些药物可以针对肥胖并发症进行针对性治疗。

更新日期：2024-09-06

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南